AbbVie Raises Annual Profit Forecast After Strong Quarter

The pharmaceutical giant lifted its earnings outlook following better-than-expected sales of key immunology and neuroscience drugs.

Updated on Oct. 30, 2026 in Biotech

Isometric editorial illustration of a modular high-tech laboratory with stainless-steel workstations and industrial piping, representing modern pharmaceutical manufacturing infrastructure. — AbbVie raised its full-year profit outlook after strong third-quarter earnings driven by high-growth immunology and neuroscience drug portfolios. AI Illustration. Upload story photo >

Live Poll

Do you trust pharmaceutical companies that rely heavily on a few top-selling drugs for growth?

AbbVie raised its annual profit forecast after reporting strong third-quarter earnings that surpassed Wall Street expectations. Robust sales of its newer immunology treatments helped the company offset lingering declines from its legacy drug Humira.

Why it matters

The company is banking on high-growth areas like neuroscience and specialized immunology to sustain its long-term performance. This transition is critical as AbbVie continues to move past the loss of patent exclusivity for its flagship product.

AbbVie reported $17.40 billion in quarterly revenue with an adjusted profit of $3.82 per share. The company now expects an annual adjusted profit range of $13.95 to $13.99 per share.

The players

AbbVie

This American biopharmaceutical company focuses on developing advanced therapies for complex diseases including immunology and neuroscience.

Apogee Therapeutics

This biotechnology firm was acquired by AbbVie to expand its development pipeline and clinical research capabilities.

The details

Skyrizi sales reached $5.78 billion while Rinvoq generated $2.71 billion in revenue during the quarter. Additionally, the company saw its neuroscience portfolio climb 19% to reach $3.39 billion in revenue.

Humira lost its US patent exclusivity in 2023.
AbbVie acquired Apogee Therapeutics in June 2026.
Shares hit a record high of $290.79 on October 29, 2026.
The company raised its annual profit forecast on October 30, 2026.
The Apogee acquisition is expected to contribute to earnings by 2032.

Market Landscape

AbbVie's strategy to bolster its revenue through aggressive acquisitions marks a departure from its historical reliance on Humira's dominance under the Hatch-Waxman Act's framework for drug patent expiration. This pivot positions the firm to compete more effectively against rivals by diversifying its portfolio into high-growth therapeutic areas.

Investors and stakeholders are observing how the company manages the cost of its $10.9 billion acquisition alongside its current revenue growth. While the acquisition is expected to impact short-term profit margins through 2027, the firm remains focused on long-term earnings potential.

The takeaway

The company's ability to maintain high revenue figures despite the loss of patent exclusivity on legacy products demonstrates the effectiveness of its diversified growth strategy. Investors should continue to monitor the integration of new acquisitions as the firm balances immediate costs with long-term earnings targets.